The Impact of KRAS Mutation in Patients With Sporadic Nonampullary Duodenal Epithelial Tumors.
Adenocarcinoma
/ genetics
Adult
Aged
Aged, 80 and over
B7-H1 Antigen
/ analysis
Duodenal Neoplasms
/ genetics
Female
Fusobacterium nucleatum
/ isolation & purification
Gastric Mucosa
/ pathology
Humans
Male
Middle Aged
Mutation
Neoplasm Staging
Phenotype
Proto-Oncogene Proteins B-raf
/ genetics
Proto-Oncogene Proteins p21(ras)
/ genetics
Journal
Clinical and translational gastroenterology
ISSN: 2155-384X
Titre abrégé: Clin Transl Gastroenterol
Pays: United States
ID NLM: 101532142
Informations de publication
Date de publication:
18 11 2021
18 11 2021
Historique:
received:
21
06
2021
accepted:
23
09
2021
entrez:
19
11
2021
pubmed:
20
11
2021
medline:
2
2
2022
Statut:
epublish
Résumé
The genomic characterization of primary nonampullary duodenal adenocarcinoma indicates a genetic resemblance to gastric and colorectal cancers. However, a correlation between the clinical and molecular characteristics of these cancers has not been established. This study aimed to elucidate the clinicopathological features of sporadic nonampullary duodenal epithelial tumors, including their molecular characteristics and prognostic factors. One hundred forty-eight patients with sporadic nonampullary duodenal epithelial tumors were examined in this study. Patient sex, age, TNM stage, tumor location, treatment methods, histology, KRAS mutation, BRAF mutation, Fusobacterium nucleatum, mucin phenotype, and programmed death-ligand 1 (PD-L1) status were evaluated. KRAS and BRAF mutations, Fusobacterium nucleatum, mucin phenotype, and PD-L1 status were analyzed by direct sequencing, quantitative polymerase chain reaction, and immunochemical staining. The median follow-up duration was 119.4 months. There were no deaths from duodenal adenoma (the primary disease). Kaplan-Meier analysis for duodenal adenocarcinoma showed a significant effect of TNM stage (P < 0.01). In univariate analysis of primary deaths from duodenal adenocarcinoma, TNM stage II or higher, undifferentiated, KRAS mutations, gastric phenotype, intestinal phenotype, and PD-L1 status were significant factors. In multivariate analysis, TNM stage II or higher (hazard ratio: 1.63 × 1010, 95% confidence interval: 18.66-6.69 × 1036) and KRAS mutation (hazard ratio: 3.49, confidence interval: 1.52-7.91) were significant factors. Only KRAS mutation was a significant prognostic factor in primary sporadic nonampullary duodenal adenocarcinoma in cases in which TNM stage was considered.
Identifiants
pubmed: 34797780
doi: 10.14309/ctg.0000000000000424
pii: 01720094-202111000-00009
pmc: PMC8604005
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
KRAS protein, human
0
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e00424Informations de copyright
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.
Références
Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214–8.
Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015;21:1350–6.
Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: A systematic review and meta-analysis. JAMA Oncol 2017;3:211–9.
Shukla SK, Elias EG. Primary neoplasms of the duodenum. Surg Gynecol Obstet 1976;142:858–60.
Hoffman BP, Grayzel DM. Benign tumors of the duodenum. Am J Surg 1945;70:394–400.
Darling RC, Welch CE. Tumors of the small intestine. N Engl J Med 1959;260:397–408.
Alwmark A, Andersson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg 1980;191:13–8.
Goda K, Kikuchi D, Yamamoto Y, et al. Endoscopic diagnosis of superficial non-ampullary duodenal epithelial tumors in Japan: Multicenter case series. Dig Endosc 2014;26(Suppl 2):23–9.
Sakae H, Kanzaki H, Nasu J, et al. The characteristics and outcomes of small bowel adenocarcinoma: A multicentre retrospective observational study. Br J Cancer 2017;117:1607–13.
Okada K, Fujisaki J, Kasuga A, et al. Sporadic nonampullary duodenal adenoma in the natural history of duodenal cancer: A study of follow-up surveillance. Am J Gastroenterol 2011;106:357–64.
Matsuzaki J, Suzuki H, Shimoda M, et al. Clinical and endoscopic findings to assist the early detection of duodenal adenoma and adenocarcinoma. United European Gastroenterol J 2019;7:250–60.
Endo M, Abiko Y, Oana S, et al. Usefulness of endoscopic treatment for duodenal adenoma. Dig Endosc 2010;22:360–5.
Yuan W, Zhang Z, Dai B, et al. Whole-exome sequencing of duodenal adenocarcinoma identifies recurrent Wnt/beta-catenin signaling pathway mutations. Cancer 2016;122:1689–96.
Niwa A, Kuwano S, Tomita H, et al. The different pathogeneses of sporadic adenoma and adenocarcinoma in non-ampullary lesions of the proximal and distal duodenum. Oncotarget 2017;8:41078–90.
Matsueda K, Kanzaki H, Matsueda K, et al. The clinicopathological differences of sporadic non-ampullary duodenal epithelial neoplasm depending on tumor location. J Gastroenterol Hepatol 2019;34:1540–4.
Toba T, Inoshita N, Kaise M, et al. Clinicopathological features of superficial non-ampullary duodenal epithelial tumor; gastric phenotype of histology correlates to higher malignant potency. J Gastroenterol 2018;53:64–70.
Watari J, Mitani S, Ito C, et al. Molecular alterations and PD-L1 expression in non-ampullary duodenal adenocarcinoma: Associations among clinicopathological, immunophenotypic and molecular features. Sci Rep 2019;9:10526.
Yachida S, Mizutani S, Shiroma H, et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 2019;25:968–76.
Bertero L, Massa F, Metovic J, et al. Eighth edition of the UICC classification of malignant tumours: An overview of the changes in the pathological TNM classification criteria—What has changed and why? Virchows Arch 2018;472:519–31.
Yamamoto S, Kinugasa H, Hirai M, et al. Heterogeneous distribution of Fusobacterium nucleatum in the progression of colorectal cancer. J Gastroenterol Hepatol 2021;36(7):1869-1876.
Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000;47:251–5.
Matsubara A, Sekine S, Kushima R, et al. Frequent GNAS and KRAS mutations in pyloric gland adenoma of the stomach and duodenum. J Pathol 2013;229:579–87.
Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: The “RASCAL II” study. Br J Cancer 2001;85:692–6.
Bazan V, Migliavacca M, Zanna I, et al. Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. Ann Oncol 2002;13:1438–46.
Ogura T, Yamao K, Hara K, et al. Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer. J Gastroenterol 2013;48:640–6.
John J, Frech M, Wittinghofer A. Biochemical properties of Ha-ras encoded p21 mutants and mechanism of the autophosphorylation reaction. J Biol Chem 1988;263:11792–9.
Krengel U, Schlichting I, Scherer A, et al. Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell 1990;62:539–48.
Kaplan PL, Ozanne B. Cellular responsiveness to growth factors correlates with a cell's ability to express the transformed phenotype. Cell 1983;33:931–8.
Al-Mulla F, MacKenzie EM. Differences in in vitro invasive capacity induced by differences in Ki-Ras protein mutations. J Pathol 2001;195:549–56.
Fu T, Pappou EP, Guzzetta AA, et al. CpG island methylator phenotype-positive tumors in the absence of MLH1 methylation constitute a distinct subset of duodenal adenocarcinomas and are associated with poor prognosis. Clin Cancer Res 2012;18:4743–52.
Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: Towards implementation of circulating tumour DNA. Nat Rev Cancer 2017;17:223–38.